

C Michael Stein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12084527/publications.pdf>

Version: 2024-02-01

162
papers

14,961
citations

36691

53
h-index

21239

119
g-index

166
all docs

166
docs citations

166
times ranked

17279
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TPMT</i> and <i>NUDT15</i> Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 263-271.	2.3	14
2	Identifying Potential Therapeutic Applications and Diagnostic Harms of Increased Bilirubin Concentrations: A Clinical and Genetic Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 435-443.	2.3	4
3	Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension. <i>Nature Communications</i> , 2022, 13, 46.	5.8	19
4	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2C19</i> Genotype and Clopidogrel Therapy: 2022 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 959-967.	2.3	166
5	Brief Report: Predicted Expression of Genes Involved in the Thiopurine Metabolic Pathway and Azathioprine Discontinuation Due to Myelotoxicity. <i>Clinical and Translational Science</i> , 2022, , .	1.5	3
6	Frequency of benign neutropenia among Black versus White individuals undergoing a bone marrow assessment. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3628-3635.	1.6	5
7	Race, Genotype, and Azathioprine Discontinuation. <i>Annals of Internal Medicine</i> , 2022, 175, 1092-1099.	2.0	14
8	Effect of <i>SLCO1B1</i> Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. <i>Clinical and Translational Science</i> , 2021, 14, 343-353.	1.5	25
9	A retrospective approach to evaluating potential adverse outcomes associated with delay of procedures for cardiovascular and cancer-related diagnoses in the context of COVID-19. <i>Journal of Biomedical Informatics</i> , 2021, 113, 103657.	2.5	20
10	Plasma miRNAs improve the prediction of coronary atherosclerosis in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 2211-2219.	1.0	24
11	<i>CYP2D6</i> genotype and reduced codeine analgesic effect in real-world clinical practice. <i>Pharmacogenomics Journal</i> , 2021, 21, 484-490.	0.9	7
12	DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1421-1430.	2.2	10
13	Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis. <i>Lupus</i> , 2021, 30, 1264-1272.	0.8	2
14	A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes. <i>JAMA Network Open</i> , 2021, 4, e2112820.	2.8	16
15	High-throughput framework for genetic analyses of adverse drug reactions using electronic health records. <i>PLoS Genetics</i> , 2021, 17, e1009593.	1.5	5
16	Association Between a Common, Benign Genotype and Unnecessary Bone Marrow Biopsies Among African American Patients. <i>JAMA Internal Medicine</i> , 2021, 181, 1100.	2.6	18
17	Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003709.	3.9	14
18	Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003341.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2395.	3.8	60
20	Development and Validation of a MicroRNA Panel to Differentiate Between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. <i>Journal of Rheumatology</i> , 2020, 47, 188-196.	1.0	33
21	Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 534-543.	1.5	20
22	The Endogenous Plasma Small RNAome of Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 97-105.	0.9	16
23	Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study. <i>Pharmacogenomics Journal</i> , 2020, 20, 462-470.	0.9	18
24	Circulating microbial small RNAs are altered in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1557-1564.	0.5	9
25	PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1675-1687.	2.2	28
26	Ambulatory blood pressure in patients with systemic lupus erythematosus: Association with markers of immune activation. <i>Lupus</i> , 2020, 29, 1683-1690.	0.8	8
27	Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. <i>Pharmacogenomics Journal</i> , 2020, 20, 831-839.	0.9	5
28	Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. <i>American Journal of Human Genetics</i> , 2020, 106, 707-716.	2.6	93
29	Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways. <i>Kidney International</i> , 2020, 97, 1032-1041.	2.6	20
30	Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice. <i>Pharmacogenomics Journal</i> , 2020, 20, 736-745.	0.9	6
31	Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Real-World Data From Electronic Health Records. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 934-943.	2.3	26
32	Pleiotropy in the Genetic Predisposition to Rheumatoid Arthritis: A Phenome-wide Association Study and Inverse Variance-Weighted Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1483-1492.	2.9	10
33	Increased vascular β -1-adrenergic receptor sensitivity in older adults with posttraumatic stress disorder. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2020, 319, R611-R616.	0.9	8
34	Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 48-53.	0.9	5
35	Vascular β -1-adrenergic sensitivity is enhanced in chronic kidney disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R485-R490.	0.9	11
36	A Genetic Approach to the Association Between PCSK9 and Sepsis. <i>JAMA Network Open</i> , 2019, 2, e1911130.	2.8	25

#	ARTICLE	IF	CITATIONS
37	Variants in BMI-Associated Genes and Adrenergic Genes are not Associated with Gestational Weight Trajectory. <i>Obesity</i> , 2019, 27, 1184-1189.	1.5	3
38	A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. <i>Npj Genomic Medicine</i> , 2019, 4, 3.	1.7	26
39	Co-prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 703-709.	2.3	13
40	Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1862-1869.	2.9	46
41	Association Between Low-Density Lipoprotein Cholesterol Levels and Risk for Sepsis Among Patients Admitted to the Hospital With Infection. <i>JAMA Network Open</i> , 2019, 2, e187223.	2.8	40
42	Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. <i>JAMA Psychiatry</i> , 2019, 76, 162.	6.0	74
43	Association between urinary sodium and potassium excretion and blood pressure and inflammation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 895-900.	1.0	8
44	LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. <i>Circulation</i> , 2018, 138, 1839-1849.	1.6	64
45	Secretory sphingomyelinase (S-SMase) activity is elevated in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1395-1399.	1.0	9
46	Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases. <i>Annals of Internal Medicine</i> , 2018, 169, 355.	2.0	5
47	Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2221.	3.8	153
48	A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. <i>Nature Communications</i> , 2018, 9, 3522.	5.8	13
49	Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. <i>PLoS Medicine</i> , 2018, 15, e1002642.	3.9	22
50	Validation of discharge diagnosis codes to identify serious infections among middle age and older adults. <i>BMJ Open</i> , 2018, 8, e020857.	0.8	55
51	Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases. <i>Annals of Internal Medicine</i> , 2018, 168, 396.	2.0	75
52	Replication and fine-mapping of genetic predictors of lipid traits in African-Americans. <i>Journal of Human Genetics</i> , 2017, 62, 895-901.	1.1	9
53	Coronary Artery Calcification and Rheumatoid Arthritis: Lack of Relationship to Risk Alleles for Coronary Artery Disease in the General Population. <i>Arthritis and Rheumatology</i> , 2017, 69, 529-541.	2.9	12
54	High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 190-195.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-€Controlled Case Series Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 323-331.	2.9	67
56	Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 215, 482-486.	0.8	8
57	Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. <i>IJC Metabolic & Endocrine</i> , 2016, 13, 6-11.	0.5	15
58	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. <i>Gastroenterology</i> , 2016, 151, 1105-1112.e10.	0.6	78
59	Drugs That May Cause or Exacerbate Heart Failure. <i>Circulation</i> , 2016, 134, e32-69.	1.6	320
60	Identifying genetically driven clinical phenotypes using linear mixed models. <i>Nature Communications</i> , 2016, 7, 11433.	5.8	12
61	Genetic determinants of variability in warfarin response after the dose-titration phase. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 510-516.	0.7	4
62	Telomere Length and Coronary Atherosclerosis in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1469-1474.	1.0	13
63	Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2415.	3.8	308
64	Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2099-2105.	2.9	35
65	Time-Course Analysis of Flow Mediated Dilation for the Evaluation of Endothelial Function After a High-Fat Meal in African Americans. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	9
66	Out-of-Hospital Mortality Among Patients Receiving Methadone for Noncancer Pain. <i>JAMA Internal Medicine</i> , 2015, 175, 420.	2.6	63
67	Academic clinical research: Death by a thousand clicks. <i>Science Translational Medicine</i> , 2015, 7, 318fs49.	5.8	2
68	Genetics of serum concentration of IL-6 and TNF± in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. <i>Clinical Rheumatology</i> , 2015, 34, 1375-1382.	1.0	56
69	Urinary Albumin Excretion Is Increased in Patients with Rheumatoid Arthritis and Associated with Arterial Stiffness. <i>Journal of Rheumatology</i> , 2015, 42, 593-598.	1.0	13
70	A Variant in the Osteoprotegerin Gene Is Associated with Coronary Atherosclerosis in Patients with Rheumatoid Arthritis: Results from a Candidate Gene Study. <i>International Journal of Molecular Sciences</i> , 2015, 16, 3885-3894.	1.8	12
71	Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 25-31.	2.1	49
72	Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 117.	1.6	59

#	ARTICLE	IF	CITATIONS
73	Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise. <i>Physiological Genomics</i> , 2015, 47, 400-406.	1.0	6
74	Development of an algorithm to identify serious opioid toxicity in children. <i>BMC Research Notes</i> , 2015, 8, 293.	0.6	18
75	Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1746-1751.	1.0	48
76	Effect of Omega-Three Polyunsaturated Fatty Acids on Inflammation, Oxidative Stress, and Recurrence of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015, 115, 196-201.	0.7	52
77	Genotype and risk of major bleeding during warfarin treatment. <i>Pharmacogenomics</i> , 2014, 15, 1973-1983.	0.6	50
78	Is Visceral Fat the Missing Link in the Relationship Between Inflammation and Insulin Resistance in RA?. <i>Journal of Rheumatology</i> , 2014, 41, 1906-1909.	1.0	1
79	Suboptimal Inhibition of Platelet Cyclooxygenase 1 by Aspirin in Systemic Lupus Erythematosus: Association With Metabolic Syndrome. <i>Arthritis Care and Research</i> , 2014, 66, 285-292.	1.5	8
80	Genetic variation in the β_1 -adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. <i>American Heart Journal</i> , 2014, 167, 101-108.e1.	1.2	12
81	Response to Is Creatine Kinase the Intrinsic Factor of Smooth Muscle Enhancing Vascular Contractility in Subjects of African Ancestry?. <i>Hypertension</i> , 2013, 62, .	1.3	0
82	Warfarin pharmacogenomics in children. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1402-1407.	0.8	16
83	A polymorphism in the protein kinase C gene PRKCB is associated with β_2 -adrenoceptor-mediated vasoconstriction. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 127-134.	0.7	5
84	Epicardial adipose tissue is increased in patients with systemic lupus erythematosus. <i>Atherosclerosis</i> , 2012, 223, 389-393.	0.4	34
85	Validation of a computer case definition for sudden cardiac death in opioid users. <i>BMC Research Notes</i> , 2012, 5, 473.	0.6	11
86	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 232-240.	1.8	62
87	Azithromycin and the Risk of Cardiovascular Death. <i>New England Journal of Medicine</i> , 2012, 366, 1881-1890.	13.9	826
88	CYP2A6 genetic variation and dexmedetomidine disposition. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 937-942.	0.8	42
89	Polymorphisms in VKORC1, CYP2C9, and CYP4F2 and Warfarin Dose in the Pediatric Population. <i>Blood</i> , 2012, 120, 4358-4358.	0.6	0
90	ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. <i>New England Journal of Medicine</i> , 2011, 365, 1896-1904.	13.9	351

#	ARTICLE	IF	CITATIONS
91	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. <i>Blood</i> , 2011, 118, 3163-3171.	0.6	81
92	Atherosclerosis and Tissue Injury in Systemic Lupus Erythematosus. , 2011, , 513-522.		0
93	Independent regulation of $\hat{1}$ and $\hat{2}$ adrenergic receptor-mediated vasoconstriction in vivo. <i>Journal of Hypertension</i> , 2011, 29, 251-256.	0.3	14
94	An automated database case definition for serious bleeding related to oral anticoagulant use. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 560-566.	0.9	291
95	Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 535-541.	1.5	39
96	Pharmacogenomics. <i>Circulation</i> , 2011, 123, 1661-1670.	1.6	162
97	Genetic Variations in the $\hat{2A}$ -Adrenoreceptor Are Associated With Blood Pressure Response to the Agonist Dexmedetomidine. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 179-187.	5.1	27
98	A computer case definition for sudden cardiac death. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 563-572.	0.9	45
99	Desensitization of vascular response in vivo: contribution of genetic variation in the $\hat{2B}$ -adrenergic receptor subtype. <i>Journal of Hypertension</i> , 2010, 28, 278-284.	0.3	23
100	The Ethics of Placebo in Studies with Fracture End Points in Osteoporosis. <i>New England Journal of Medicine</i> , 2010, 363, 1367-1370.	13.9	14
101	Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors. <i>Annals of Internal Medicine</i> , 2010, 152, 337.	2.0	198
102	Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. <i>New England Journal of Medicine</i> , 2009, 360, 225-235.	13.9	1,042
103	Cardiovascular Effects of Noncardiovascular Drugs. <i>Circulation</i> , 2009, 120, 1123-1132.	1.6	27
104	Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. <i>Lupus</i> , 2009, 18, 799-806.	0.8	155
105	Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 155-163.	0.9	121
106	Clopidogrel and the Concept of High-Risk Pharmacokinetics. <i>Circulation</i> , 2009, 119, 2127-2130.	1.6	69
107	Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1580-1585.	6.7	192
108	Oxidative stress in fibromyalgia and its relationship to symptoms. <i>Clinical Rheumatology</i> , 2009, 28, 435-438.	1.0	41

#	ARTICLE	IF	CITATIONS
109	Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. <i>Blood</i> , 2009, 113, 3925-3930.	0.6	79
110	Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2008, 27, 1227-1233.	1.0	28
111	Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. <i>Arthritis and Rheumatism</i> , 2008, 58, 2105-2112.	6.7	196
112	Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors. <i>Archives of Drug Information</i> , 2008, 1, 23-28.	1.6	9
113	Genetic Determinants of Response to Warfarin during Initial Anticoagulation. <i>New England Journal of Medicine</i> , 2008, 358, 999-1008.	13.9	516
114	A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. <i>Blood</i> , 2008, 112, 1022-1027.	0.6	410
115	Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 1789-94.	1.0	86
116	N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification. <i>Journal of Rheumatology</i> , 2008, 35, 1314-9.	1.0	16
117	Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 981-986.	0.8	27
118	High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 208-214.	0.5	219
119	Clinical Pharmacology & Therapeutics Annual Report 2005. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 401-403.	2.3	1
120	β2-Adrenoceptor Genotype and Function Affect Hemodynamic Profile Heterogeneity in Postural Tachycardia Syndrome. <i>Hypertension</i> , 2006, 47, 421-427.	1.3	17
121	CP&T articles in press will be available online. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 457-457.	2.3	0
122	Clinical Pharmacology & Therapeutics annual report 2004. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 99-101.	2.3	3
123	Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. <i>Arthritis and Rheumatism</i> , 2005, 52, 1349-1359.	6.7	7
124	Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors. <i>Arthritis and Rheumatism</i> , 2005, 52, 3045-3053.	6.7	314
125	Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification. <i>Vascular Health and Risk Management</i> , 2005, 1, 357-360.	1.0	17
126	High frequency of use of rofecoxib at greater than recommended doses: cause for concern. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 339-343.	0.9	15

#	ARTICLE	IF	CITATIONS
127	\$\alpha_1A\$-adrenergic receptor polymorphism and vascular response*1, *2. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 539-545.	2.3	23
128	Clinical Pharmacology & Therapeutics Annual Report 2003. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 189-191.	2.3	0
129	Publishing work sponsored by the tobacco industry. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 517-518.	2.3	3
130	Genetic variability in CYP3A5 and its possible consequences. <i>Pharmacogenomics</i> , 2004, 5, 243-272.	0.6	261
131	New Drugs for Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2004, 350, 2167-2179.	13.9	591
132	Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. <i>New England Journal of Medicine</i> , 2004, 351, 1089-1096.	13.9	470
133	\$\beta_2\$-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 517-522.	5.7	54
134	Clinical Pharmacology & Therapeutics—An update. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 1-3.	2.3	0
135	Managing risk in healthy subjects participating in clinical research. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 511-512.	2.3	11
136	Clinical pharmacology & therapeutics annual report 2002. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 99-101.	2.3	0
137	Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2003, 349, 2407-2415.	13.9	773
138	Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. <i>Lancet</i> , The, 2002, 359, 118-123.	6.3	324
139	COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. <i>Lancet</i> , The, 2002, 360, 1071-1073.	6.3	501
140	CYP2C9 allelic variants: ethnic distribution and functional significance. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1257-1270.	6.6	309
141	Are herbal products dietary supplements or drugs? An important question for public safety. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 411-413.	2.3	30
142	The Effect of Common Polymorphisms of the \$\beta_2\$-Adrenergic Receptor on Agonist-Mediated Vascular Desensitization. <i>New England Journal of Medicine</i> , 2001, 345, 1030-1035.	13.9	344
143	MOLECULAR BASIS OF ETHNIC DIFFERENCES IN DRUG DISPOSITION AND RESPONSE. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 815-850.	4.2	552
144	Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans. <i>Molecular Pharmacology</i> , 2001, 60, 382-387.	1.0	268

#	ARTICLE	IF	CITATIONS
145	Educational Program for Physicians to Reduce Use of Non-Steroidal Anti-Inflammatory Drugs Among Community-Dwelling Elderly Persons. <i>Medical Care</i> , 2001, 39, 425-435.	1.1	51
146	Arg389Gly β 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 191-197.	5.7	100
147	Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 95-110.	5.7	30
148	The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 270-279.	2.3	66
149	Human β 2-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 670-675.	2.3	70
150	CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5' promoter region polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 82-91.	2.3	214
151	Increased Vascular Adrenergic Vasoconstriction and Decreased Vasodilation in Blacks. <i>Hypertension</i> , 2000, 36, 945-951.	1.3	127
152	Inhibition of P-Glycoprotein-Mediated Drug Transport. <i>Circulation</i> , 1999, 99, 552-557.	1.6	407
153	Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature. <i>Hypertension</i> , 1999, 33, 1431-1435.	1.3	147
154	ACR 20: Clinical or statistical significance?. <i>Arthritis and Rheumatism</i> , 1999, 42, 1572-1576.	6.7	42
155	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 539-550.	5.7	164
156	β 1A-Adrenergic receptor polymorphism. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 651-656.	5.7	48
157	Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 662-668.	2.3	2
158	Vasodilation in black Americans: Attenuated nitric oxide-mediated responses*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 436-443.	2.3	142
159	Implementation of multiple outpatient formularies: Undesirable effects*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 1-7.	2.3	35
160	Blunted Blood Pressure Response to Central Sympathoinhibition in Normotensive Blacks. <i>Hypertension</i> , 1997, 30, 157-162.	1.3	29
161	Attenuation of Isoproterenol-Mediated Vasodilatation in Blacks. <i>New England Journal of Medicine</i> , 1995, 333, 155-160.	13.9	160
162	Dietary Sodium Intake Modulates Vasodilation Mediated by Nitroprusside But Not by Methacholine in the Human Forearm. <i>Hypertension</i> , 1995, 25, 1220-1223.	1.3	19